Special Issue Article
Multi-modality Therapy of Hepatic Metastases from Colorectal Carcinoma: Optimal Combination of Systemic Chemotherapy with Radio-embolizationEsme J. Hill1,2 and Ricky A. Sharma1,2*
- *Corresponding Author:
- Ricky A. Sharma
Gray Institute, Department of Oncology
Old Road Campus Research Building
University of Oxford, Oxford OX3 7DQ, UK
E-mail: [email protected]
Received date: April 26, 2011; Accepted date: May 26, 2011; Published date: June 15, 2011
Citation: Hill EJ, Sharma RA (2011) Multi-modality Therapy of Hepatic Metastases from Colorectal Carcinoma: Optimal Combination of Systemic Chemotherapy with Radio-embolization. J Nucl Med Radiat Ther 2:108. doi: 10.4172/2155-9619.1000108
Copyright: © 2011 Hill EJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The commonest cause of death from advanced colorectal cancer is disease progression of hepatic metastases. A number of technologies are in clinical development to improve local control of liver metastases and potentially improve overall survival. Radio-embolization (RE) is a technique for administering resin or glass microspheres that contain yttrium-90 to unresectable primary or secondary hepatic malignancies internally via the liver's arterial supply in a single procedure. Clinical trials of RE used with concomitant radiosensitizing chemotherapy have shown promising results in patients with metastatic colorectal cancer. In this article, the evidence base for combining RE with systemic chemotherapy in the first line therapy of metastatic colorectal cancer is appraised and the scientific rationale for combining RE with chemotherapy in first and subsequent lines of therapy is outlined. Clinical trials of RE and chemotherapy currently recruiting patients with metastatic colorectal cancer are discussed in detail and practical recommendations offered on how best to combine RE and systemic chemotherapy.